A.I. Burnasyan  FMBC clinical bulletin. 2025 № 4

T.Sh. Sadekov, O.G. Zhilenkova, E.R. Mekhtiev

Biotechnological Approaches to Studying Lipid Profile in Neoplasia
by Concentrations of Minor Lipid Components in Blood

G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology, Russia

Contact person: SadekovTimur Shamil’evich:  timur-sadekov@mail.ru

 

Abstract
Colorectal cancer and other intestinal neoplasms remain among the leading causes of cancer-related mortality worldwide. The disease is often diagnosed at advanced stages, which limits therapeutic options and worsens prognosis. Therefore, the development of novel, non-invasive, and highly sensitive methods for early detection is of paramount importance. One promising approach involves the study of the blood lipid profile, particularly minor lipid components (MLCs), which reflect tumor-associated metabolic alterations.

Purpose: To develop a methodology for determining the lipid profile of biomarkers in intestinal neoplasms based on minor lipid components of blood.

Material and methods: the study included 497 participants, comprising 151 patients with confirmed intestinal neoplasms and 346 clinically healthy controls. Venous blood samples were collected after overnight fasting. Fatty acid compounds were analyzed using gas chromatography coupled with mass spectrometry (GC–MS). Statistical analysis involved descriptive methods and Ward’s hierarchical clustering (STATISTICA 8.0).

Results: significant differences in MLC concentrations were identified between groups (p < 0.05). Cluster analysis highlighted the most informative compounds (10h18, 10Me16, i17:1d9, 17:1d9, i16, i15), characterized by strong correlations and varying degrees of change. ROC analysis confirmed the diagnostic value of several metabolites. The highest performance was demonstrated by isopentadecanoic acid i17:1d9 (AUC = 0.978, Se = 92.1%, Sp = 95.7%, PPV = 90.3%, NPV = 96.5%). High diagnostic accuracy was also shown for 10-hydroxystearic acid 10h18 (AUC = 0.861, Se = 90.1%, Sp = 73.1%). Other compounds – 10Me16, 17:1d9, i16, and i15 – showed moderate or low AUC values, limiting their utility in diagnostics.

Conclusion: minor lipid components of blood reflect characteristic metabolic shifts associated with intestinal neoplasms and may serve as informative biomarkers for early detection. The most significant diagnostic potential was observed for isopentadecanoic acid i17:1d9 and 10-hydroxystearic acid 10h18, which could be incorporated into multiparametric diagnostic panels. Integration of MLC analysis into screening programs may improve early colorectal cancer detection and support personalized approaches to diagnosis and disease monitoring.

Keywords: neoplasia, colorectal cancer, lipid profile, minor lipid components, gas chromatography–mass spectrometry (GC-MS), biomarkers, metabolomics

For citation: Sadekov TSh, Zhilenkova OG, Mekhtiev ER. Biotechnological Approaches to Studying Lipid Profile in Neoplasia by Concentrations of Minor Lipid Components in Blood. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2025.4:65-70. (In Russian) DOI: 10.33266/2782-6430-2025-4-65-70

 

REFERENCES

1. Bezrodnyy S.L., Mardanly S.G., Zatevalov A.M., Tereshina Ye.V., Kiseleva V.A., Pomazanov V.V. Prediktivnaya Diagnostika Sakharnogo Diabeta 2 Tipa i Sochetannoy Dislipidemii po Analizu Eksposoma Cheloveka = Predictive Diagnostics of Type 2 Diabetes Mellitus and Combined Dyslipidemia by Human Exposome Analysis. A Tutorial for the System of Postgraduate Professional Education of Doctors. Orekhovo-Zuyevo Publ., 2021. 40 p. (In Russ.).
2. Zatevalov A.M., Sel’kova Ye.P., Afanas’yev S.S., Aleshkin A.V., Mironov A.Yu., Gusarova M.L., Gudova N.V. Assessment of the Degree of Microbiological Disorders of the Microflora of the Oropharynx and Intestines Using Mathematical Modeling Methods. Klinicheskaya Laboratornaya Diagnostika = Clinical Laboratory Diagnostics. 2016;61;2:117–121 (In Russ.).
3. Fedorov D.S., Kalyuzhin O.V., Afanas’yev S.S., Zatevalov A.M, Zhilenkova O.G. Screening Diagnostics of Bowel Cancer Based on the Results of Meta-Exposomal Study. Epidemiologiya i Infektsionnyye Bolezni = Epidemiology and Infectious Diseases. 2024;29;1:58–64 (In Russ.). Doi: 10.51620/EIB-2024-29-1-58-64. EDN: DPXKGK.
4. Farshidfar F., Weljie A., Kopciuk K., et al. A Validated Metabolomic Signature for Colorectal Cancer: Exploration of the Clinical Value of Metabolomics. Br J Cancer. 2016;115:848-857. Doi: 10.1038/bjc.2016.271.
5. Pakiet A., Kobiela J., Stepnowski P., et al. Changes in Lipids Composition and Metabolism in Colorectal Cancer: a Review. Lipids Health Dis. 2019;18:29. Doi: 10.1186/s12944-019-0977-8.
6. Răchieriu C., Eniu D.T., Moiş E., Graur F., Socaciu C., Socaciu M.A., Hajjar N.A. Lipidomic Signatures for Colorectal Cancer Diagnosis and Progression Using UPLC-QTOF-ESI+MS. Biomolecules. 2021;11;3:417. Doi: 10.3390/biom11030417.
7. Sun Y., Liu B., Chen Y., Xing Y., Zhang Y. Multi-Omics Prognostic Signatures Based on Lipid Metabolism for Colorectal Cancer. Front Cell Dev Biol. 2022;9:811957. Doi: 10.3389/fcell.2021.811957.

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 07.08.2025. Accepted for publication: 02.09.2025